Navigation Links
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Date:12/11/2007

al trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, the risk that Soliris will not generate interest among physicians, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2007 and in our other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward- looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

----------

(1) Bessler M, Schrezenmeier H, Maciejewski JP, et al. Significant

Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with

Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion:

Clinical Improvement with Eculizumab Therapy. Presented during oral

sessions at the 49th Annual Meeting of the American Society of

Hematology Meeting. December 11, 2007.

(2) Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of

intravascular hemolysis and extracellular plasma hemoglobin: a novel

mechanism of human disease. JAMA. 2005;293:1653-1662.

(3) Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history

of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253-

1258.
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... SAN DIEGO , July 30, 2014 /PRNewswire/ ... held biotech company that designs and develops novel ... management of cancer, announced today the completion of ... The financing included new investors RusnanoMedInvest (RMI) and ... Fund, and Pfizer Venture Investments, as well as ...
(Date:7/30/2014)... , July 30, 2014 ... and CUDA programming expertise to big data, aerospace ... eInfochips, a leading engineering R&D services ... to develop NVIDIA GPU-powered solutions for aerospace ... high-performance computing (HPC), industrial , and ...
(Date:7/29/2014)... CAMBRIDGE, Mass. and HERZLIYA PITUACH, ... Inc. (OTCQX and NASDAQ OMX First North Premier, ... announces today that it has initiated the screening of ... trial exploring the safety and efficacy of bertilimumab in ... open-label trial will enroll 10-15 patients who will receive ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5
(Date:7/31/2014)... National non-profit World T.E.A.M. Sports’ annual Adventure ... 12-14, following two years in the high Colorado Plateau. ... and able-bodied athletes competing together in an inclusive outdoor ... experienced adventure athletes. , Hosted at the rustic ... River in the rugged Gore Mountains northwest of Vail, ...
(Date:7/31/2014)... July 31, 2014 In its latest blog ... and believes that having family close by during a stay ... not the process is successful, is looking at 10 tips ... , “Addiction recovery is a lifelong process, and one ... be committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
(Date:7/31/2014)... When guests shop CVS, they’ll find many ... Shea Moisture. And now CVS is adding another acclaimed brand ... 1, guests will find G Natural products in CVS stores ... CEO Roger Gore was inspired to start G’Natural Herbal Products ... developing a receding hairline; he tried many products on the ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 Push to ... ninth annual national “Shop For A Cause” charity shopping ... Cause” is a unique one-day-only shopping event created to ... more than $44 million for charities across the country ... by purchasing shopping passes from Push to Walk now. ...
(Date:7/30/2014)... July 31, 2014 Responding to ... environment more responsive to an increasingly diverse patient ... experience and scholarly expertise to the publication of ... care professions: "Diversity and Cultural Competence in Health ... L. Dreachslin, PhD, a professor in the Management ...
Breaking Medicine News(10 mins):Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 3Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:CVS Caremark Adds New, Natural Acclaimed Hair Care Line to its Beauty Roster 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3
... , , , LOUISVILLE, Ky., July ... regional provider of home health nursing services, announced today that it will ... on Wednesday, August 5, 2009, before the market open. , , ... 11:00 a.m. ET on August 5, 2009, and will be hosted by ...
... , WASHINGTON, July 31 Last ... Democratic leadership,s health care bill, H.R. 3200, that would specifically include ... of this bill. Family Research Council Action President Tony Perkins had ... Energy and Commerce Committee mark up: , , ...
... , , , , ... , HARRISBURG, Pa., July 31 Department of ... observance of National Immunization Awareness Month. , , ... sure you and your family are up-to-date on these immunizations is ...
... , , , ... statement by Jim O,Hara, Director, Produce Safety Project: , , ... the safety of fresh produce. The proposed guidance documents put out ... that the agency will finalize these documents quickly. We also look ...
... linked to headache, researchers explain , FRIDAY, July 31 ... cosmetic surgery, Michelle Cramer has now lost most of ... her frown lines. , Cramer, a graphics illustrator in ... close to a decade until she had surgery to ...
... , , , ABA program ... CALDWELL, N.J., July 31 Caldwell College will launch ... Analysis (ABA), a well developed scientific discipline that is best known ... disorder. Caldwell,s program was recently approved by the New Jersey ...
Cached Medicine News:Health News:Almost Family, Inc. to Report Second Quarter 2009 Financial Results on August 5, 2009 2Health News:House Measure Proves Healthcare Legislation Will Fund Abortion, Says Family Research Council Action 2Health News:Pennsylvania Secretary of Health Urges Pennsylvanians to Get Immunized 2Health News:Pennsylvania Secretary of Health Urges Pennsylvanians to Get Immunized 3Health News:Plastic Surgery Technique Might Ease Migraines 2Health News:Plastic Surgery Technique Might Ease Migraines 3Health News:Caldwell College Receives Approval to Launch First Ph.D. for Applied Behavior Analysis-Autism Treatment in New Jersey 2
... Merit Medical is pleased to offer ... The pre-coated, high-performance, InQwire guide wire ... is very lubricious and can help ... available in a wide range of ...
... The MULTI-LINK VISION Coronary Stent System ... of cobalt chromium stents. Cobalt chromium is ... so a cobalt chromium stent can have ... stainless steel stent with struts that are ...
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary ... antiproliferative drug, called "sirolimus", a ... stent delivery platform. Upon placement, ... wall and impedes the process ...
Medicine Products: